Form 8-K - Current report:
SEC Accession No. 0001641172-25-021118
Filing Date
2025-07-28
Accepted
2025-07-28 09:29:25
Documents
19
Period of Report
2025-07-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 48375
2 EX-4.1 ex4-1.htm EX-4.1 96531
3 EX-4.2 ex4-2.htm EX-4.2 112856
4 EX-5.1 ex5-1.htm EX-5.1 16676
5 EX-10.1 ex10-1.htm EX-10.1 253656
6 EX-10.2 ex10-2.htm EX-10.2 83107
7 EX-99.1 ex99-1.htm EX-99.1 13388
  Complete submission text file 0001641172-25-021118.txt   921308

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE thar-20250723.xsd EX-101.SCH 3020
9 XBRL LABEL FILE thar-20250723_lab.xml EX-101.LAB 34239
10 XBRL PRESENTATION FILE thar-20250723_pre.xml EX-101.PRE 22362
22 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3678
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41210 | Film No.: 251153358
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)